AstraZeneca asthma inhaler Trixeo wins positive EU CHMP opinion for approval

AstraZeneca's Trixeo Aerosphere received a positive CHMP opinion for EU approval as a maintenance treatment for asthma in patients aged 12 and older. This recommendation, supported by Phase III KALOS and LOGOS data demonstrating improved lung function and reduced exacerbation rates compared to ICS/LABA therapy, would establish a second European indication for the drug beyond COPD.

AstraZeneca’s Trixeo Aerosphere won a positive CHMP opinion for EU approval in maintenance asthma treatment for patients aged 12 and older. * Recommendation was backed by Phase III KALOS and LOGOS data showing improved lung function, lower annualized severe exacerbation rates versus ICS/LABA therapy. * Clearance would add a second European indication for Trixeo beyond COPD. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here